Wells Fargo
FATE icon

Wells Fargo’s Fate Therapeutics FATE Stock Holding History

Wells Fargo’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,000
Closed -$74K – 6611
2020
Q3 		$74K Buy
+17,000
New +$594K ﹤0.01% 5367

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wells Fargo's FATE Position: Q2 2026 in Review

Wells Fargo reduced its Fate Therapeutics (FATE) stake by 37% in Q2 2026, selling an estimated $69.1K and leaving 63,646 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #5287.

Wells Fargo first reported a position in FATE in Q1 2014 and has held it in 48 quarters since. The position peaked at $28.4M in Q2 2021. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Wells Fargo held 63,646 shares of Fate Therapeutics worth $172K as of Q2 2026.
  • Wells Fargo sold 37,329 Fate Therapeutics shares in Q2 2026, an estimated $69.1K.
  • Fate Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5287 holding.
  • Wells Fargo first reported a position in Fate Therapeutics in Q1 2014 and has held it in 48 quarters since.
  • Wells Fargo's Fate Therapeutics position peaked at $28.4M in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.